Additionally, the 36-month beta value for CARM is 1.56. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CARM is 21.35M and currently, short sellers hold a 4.90% ratio of that float. The average trading volume of CARM on November 08, 2024 was 138.90K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CARM) stock’s latest price update
Carisma Therapeutics Inc (NASDAQ: CARM)’s stock price has dropped by -7.21 in relation to previous closing price of 1.11. Nevertheless, the company has seen a gain of 5.80% in its stock price over the last five trading days. prnewswire.com reported 2024-11-07 that Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical efficacy data in liver fibrosis to be presented on November 17 at AASLD – The Liver Meeting ® 2024 Cash and cash equivalents of $26.9 million expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Nov. 7, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2024, and highlighted recent business updates. “Our recent progress across clinical and preclinical programs demonstrates our commitment to pioneering therapies that address significant unmet medical needs,” said Steven Kelly, President and CEO of Carisma Therapeutics.
CARM’s Market Performance
Carisma Therapeutics Inc (CARM) has experienced a 5.80% rise in stock performance for the past week, with a 7.33% rise in the past month, and a 16.34% rise in the past quarter. The volatility ratio for the week is 5.67%, and the volatility levels for the past 30 days are at 5.14% for CARM. The simple moving average for the past 20 days is 2.96% for CARM’s stock, with a -30.46% simple moving average for the past 200 days.
Analysts’ Opinion of CARM
Many brokerage firms have already submitted their reports for CARM stocks, with BTIG Research repeating the rating for CARM by listing it as a “Buy.” The predicted price for CARM in the upcoming period, according to BTIG Research is $6 based on the research report published on April 11, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see CARM reach a price target of $10. The rating they have provided for CARM stocks is “Overweight” according to the report published on October 03rd, 2023.
Evercore ISI gave a rating of “Outperform” to CARM, setting the target price at $12 in the report published on July 06th of the previous year.
CARM Trading at 3.99% from the 50-Day Moving Average
After a stumble in the market that brought CARM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.53% of loss for the given period.
Volatility was left at 5.14%, however, over the last 30 days, the volatility rate increased by 5.67%, as shares surge +10.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.21% lower at present.
During the last 5 trading sessions, CARM rose by +5.80%, which changed the moving average for the period of 200-days by -55.22% in comparison to the 20-day moving average, which settled at $1.0004. In addition, Carisma Therapeutics Inc saw -64.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CARM
Current profitability levels for the company are sitting at:
- -3.67 for the present operating margin
- 0.77 for the gross margin
The net margin for Carisma Therapeutics Inc stands at -3.5. The total capital return value is set at -1.74. Equity return is now at value -216.21, with -75.38 for asset returns.
Based on Carisma Therapeutics Inc (CARM), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at -20.16. The debt to equity ratio resting at 10.44. The interest coverage ratio of the stock is -57.08.
Currently, EBITDA for the company is -80.47 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 0.3. The receivables turnover for the company is 10.36for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.25.
Conclusion
In conclusion, Carisma Therapeutics Inc (CARM) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
